CTRI/2020/10/028269招募中2 期
A phase II study to evaluate the efficacy of cisplatin and gemcitabine based neoadjuvant chemotherapy followed by dysphagia optimized intensity modulated radiotherapy with concomitant cisplatin and correlation of clinical outcome with serial plasma Epstein Barr Virus DNA titre in patients with locally advanced nasopharyngeal carcinoma.
AIIMS New Delhi0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Carcinoma nasopharynx stage II-IVA.,
- •Histological proof of nasopharyngeal squamous cell carcinoma (keratinizing squamous cell carcinoma, non-keratinizing squamous cell carcinoma including undifferentiated and poorly differentiated nasopharyngeal carcinoma) confirmed by p40 immunohistochemistry.,
- •Eastern Cooperative Oncology Group performance status 0-3.,
- •Absence of any uncontrolled medical comorbidity.
- •Adequate end-organ functions and bone marrow reserve.,
- •Negative viral serology markers(HIV, HBsAg, HCV).,
- •Informed Consent.
排除标准
- •ECOG performance status 4.,
- •Immunocompromised status like HIV sero-positivity, organ transplant recipients, congenital immunodeficiency syndromes.,
- •Any prior oncologic treatment with surgery, chemotherapy or radiotherapy.,
- •Any uncontrolled comorbidity which may compromise delivery of protocol defined chemotherapy and radiotherapy e.g., renal disease, hepatic disease, cardiorespiratory disease, diabetes mellitus.,
- •Other histological types of nasopharyngeal carcinomas eg. neuroendocrine carcinomas., adenocarcinomas, and salivary gland type carcinomas.
研究者
相似试验
进行中（未招募）
不适用
Study assessing efficacy of a Cisplatine – Métronomic yclophosphamidetreatment in Patients with Metastatic Triple Negative breast CancerSecondary Resistant to Anthracyclines and TaxanesTriple negative metastatic breast cancer resistant secondary to anthracyclines and taxanesMedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2012-005213-39-FRCENTRE JEAN PERRI
进行中（未招募）
1 期
Etude de phase II évaluant un traitement par cisplatine et vinorelbine orale administrés de façon hebdomadaire et radiothérapie concomitante chez le sujet âgé indépendant atteint de cancer broncho-pulmonaire non à petites cellules localisé non opérable. - RACCOSAo small cell Lung cancerMedDRA version: 9.1Level: LLTClassification code 10029519Term: Non-small cell lung cancer stage IIIEUCTR2009-012413-21-FRCHU Limoges49
招募中
1 期
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY Study.Resectable biliary tract cancersMedDRA version: 20.0Level: LLTClassification code: 10028982Term: Neoplasm biliary tract Class: 10029104CTIS2023-503295-25-00Gruppo Oncologico Del Nord Ovest108
进行中（未招募）
1 期
A study assessing the combination of TG4010 and nivolumab with standard treatment in patients with advanced non small cell lung cancer.Stage IIIB-IV non small cell lung cancer (NSCLC)MedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000015841EUCTR2016-005115-41-HUTransgene S.A.39
进行中（未招募）
1 期
A study assessing the combination of TG4010 and nivolumab with standard treatment in patients with advanced non small cell lung cancer.Stage IIIB-IV non small cell lung cancer (NSCLC)MedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2016-005115-41-BETransgene S.A.44